DBV TECHNOLOGIE/S (DBVT) Downgraded by BidaskClub to “Strong Sell”

DBV TECHNOLOGIE/S (NASDAQ:DBVT) was downgraded by stock analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Friday, November 16th. Bank of America lowered their target price on shares of DBV TECHNOLOGIE/S from $33.00 to $30.00 and set a “buy” rating for the company in a report on Friday, November 2nd. ValuEngine upgraded shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a report on Thursday, August 2nd. Stifel Nicolaus assumed coverage on shares of DBV TECHNOLOGIE/S in a report on Thursday, September 13th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Morgan Stanley lowered their target price on shares of DBV TECHNOLOGIE/S from $28.00 to $27.00 and set an “equal weight” rating for the company in a report on Tuesday, September 11th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $33.67.

Shares of NASDAQ:DBVT opened at $14.93 on Friday. DBV TECHNOLOGIE/S has a 52 week low of $14.76 and a 52 week high of $26.98. The firm has a market capitalization of $878.35 million, a price-to-earnings ratio of -4.43 and a beta of 1.23.

Several institutional investors have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd bought a new stake in DBV TECHNOLOGIE/S during the 2nd quarter valued at about $285,000. Exane Asset Management raised its holdings in shares of DBV TECHNOLOGIE/S by 17.9% in the 2nd quarter. Exane Asset Management now owns 50,000 shares of the company’s stock valued at $964,000 after purchasing an additional 7,600 shares in the last quarter. Bailard Inc. raised its holdings in shares of DBV TECHNOLOGIE/S by 57.4% in the 3rd quarter. Bailard Inc. now owns 74,000 shares of the company’s stock valued at $1,662,000 after purchasing an additional 27,000 shares in the last quarter. First Midwest Bank Trust Division raised its holdings in shares of DBV TECHNOLOGIE/S by 36.7% in the 2nd quarter. First Midwest Bank Trust Division now owns 136,986 shares of the company’s stock valued at $2,642,000 after purchasing an additional 36,798 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in shares of DBV TECHNOLOGIE/S by 842.6% in the 1st quarter. Millennium Management LLC now owns 133,256 shares of the company’s stock valued at $3,074,000 after purchasing an additional 119,119 shares in the last quarter. Hedge funds and other institutional investors own 42.92% of the company’s stock.

DBV TECHNOLOGIE/S Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Featured Article: Stop Order

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply